Prourokinase vs Standard Care for Patients With Mild Ischemic Stroke: The PUMICE Randomized Clinical Trial.

ABSTRACT:

Importance

Trials have not demonstrated superiority of alteplase or tenecteplase vs standard care in patients with mild stroke and have raised safety concerns. Prourokinase is an alternative fibrinolytic that may have a favorable safety profile, and the benefit-risk profile of prourokinase in mild stroke is unknown.

Objective

To investigate the efficacy and safety of prourokinase in mild ischemic stroke within 4.5 hours of symptom onset.

Design, setting, and participants

This was a multicenter, prospective, open-label, blinded-end point randomized clinical trial conducted from November 2022 through December 2023 with 3 months of follow-up. The trial was conducted at 89 hospitals in China. Patients with a baseline National Institutes of Health Stroke Scale score of 5 o

SUBMITTER: Xiong Y 

PROVIDER: S-EPMC11894490 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature